Genes
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
85,013 comparisons from ClinicalTrials.gov.
Most participants first33,758 with no events in either group come last2,261 to 2,280 of 85,013
| Comparison | With the outcome | Risk difference, 95% interval | Participants | Trial |
|---|---|---|---|---|
| M72AS01 Group vs Control Group: serious adverse events | 51 of 1,786 62 of 1,787 | -0.6 points -1.8 to 0.5 | 3,573 | NCT01755598 Study to Evaluate the Efficacy of GlaxoSmithKline (GSK) Biologicals' Candidate Tuberculosis (TB) Vaccine in Adults |
| PCI at Hospitals Without On-Site Cardiac Surgery vs PCI at Hospital With On-Site Cardiac Surgery: Any Repeat Revascularization | 73 of 2,689 31 of 883 | -0.8 points -2.3 to 0.4 | 3,572 | NCT01116882 Percutaneous Coronary Intervention (PCI) Outcomes in Community Versus Tertiary Settings |
| PCI at Hospitals Without On-Site Cardiac Surgery vs PCI at Hospital With On-Site Cardiac Surgery: Ischemia-driven Target Vessel Revascularization | 41 of 2,689 13 of 882 | 0.1 points -1.1 to 0.9 | 3,571 | NCT01116882 Percutaneous Coronary Intervention (PCI) Outcomes in Community Versus Tertiary Settings |
| PCI at Hospitals Without On-Site Cardiac Surgery vs PCI at Hospital With On-Site Cardiac Surgery: Ischemia-driven Target Lesion Revascularization | 36 of 2,689 12 of 882 | -0.0 points -1.1 to 0.8 | 3,571 | NCT01116882 Percutaneous Coronary Intervention (PCI) Outcomes in Community Versus Tertiary Settings |
| PCI at Hospitals Without On-Site Cardiac Surgery vs PCI at Hospital With On-Site Cardiac Surgery: Major Vascular Complications | 41 of 2,687 13 of 882 | 0.1 points -1.1 to 0.9 | 3,569 | NCT01116882 Percutaneous Coronary Intervention (PCI) Outcomes in Community Versus Tertiary Settings |
| Intervention Group vs Control Group: Number of Patients With Elevated Blood Pressures Measured and Recognized by Provider | 1,394 of 1,834 1,013 of 1,728 | 17.4 points 14.3 to 20.4 | 3,562 | NCT02798354 Reducing Diagnostic Errors in Primary Care Pediatrics (Project RedDE) |
| Intervention Group vs Control Group: Number of Patients With Elevated Blood Pressure Measured and Appropriately Acted on by Providers | 1,378 of 1,834 969 of 1,728 | 19.1 points 16.0 to 22.1 | 3,562 | NCT02798354 Reducing Diagnostic Errors in Primary Care Pediatrics (Project RedDE) |
| Intervention Group vs Control Group: Number of Patients With Elevated Blood Pressures Measured and Blood Pressure Percentiles Documented in the Chart | 1,681 of 1,834 1,233 of 1,728 | 20.3 points 17.8 to 22.8 | 3,562 | NCT02798354 Reducing Diagnostic Errors in Primary Care Pediatrics (Project RedDE) |
| Sepsis Transition and Recovery (STAR) Program vs Usual Care: Palliative Care Consultation | 430 of 2,122 234 of 1,426 | 3.9 points 1.2 to 6.4 | 3,548 | NCT04495946 Implementation and Effectiveness of Engagement and Collaborative Management to Proactively Advance Sepsis Survivorship |
| Sepsis Transition and Recovery (STAR) Program vs Usual Care: All-cause Mortality and Hospital Readmission Rate | 1,023 of 2,122 684 of 1,426 | 0.2 points -3.1 to 3.6 | 3,548 | NCT04495946 Implementation and Effectiveness of Engagement and Collaborative Management to Proactively Advance Sepsis Survivorship |
| Sepsis Transition and Recovery (STAR) Program vs Usual Care: Count of Participants With Support Service Referrals | 594 of 2,122 374 of 1,426 | 1.8 points -1.2 to 4.7 | 3,548 | NCT04495946 Implementation and Effectiveness of Engagement and Collaborative Management to Proactively Advance Sepsis Survivorship |
| Sepsis Transition and Recovery (STAR) Program vs Usual Care: All-cause Hospital Readmission Rate | 763 of 2,122 478 of 1,426 | 2.4 points -0.8 to 5.6 | 3,548 | NCT04495946 Implementation and Effectiveness of Engagement and Collaborative Management to Proactively Advance Sepsis Survivorship |
| Sepsis Transition and Recovery (STAR) Program vs Usual Care: Completed Care Preferences | 526 of 2,122 309 of 1,426 | 3.1 points 0.3 to 5.9 | 3,548 | NCT04495946 Implementation and Effectiveness of Engagement and Collaborative Management to Proactively Advance Sepsis Survivorship |
| Sepsis Transition and Recovery (STAR) Program vs Usual Care: Inpatient Mental Health Assessment | 2,048 of 2,122 1,385 of 1,426 | -0.6 points -1.8 to 0.6 | 3,548 | NCT04495946 Implementation and Effectiveness of Engagement and Collaborative Management to Proactively Advance Sepsis Survivorship |
| Sepsis Transition and Recovery (STAR) Program vs Usual Care: Inpatient Functional Assessment or Physical Therapy Consult | 1,768 of 2,122 1,196 of 1,426 | -0.6 points -3.0 to 2.0 | 3,548 | NCT04495946 Implementation and Effectiveness of Engagement and Collaborative Management to Proactively Advance Sepsis Survivorship |
| Sepsis Transition and Recovery (STAR) Program vs Usual Care: All-cause Mortality Rate | 367 of 2,122 292 of 1,426 | -3.2 points -5.9 to -0.6 | 3,548 | NCT04495946 Implementation and Effectiveness of Engagement and Collaborative Management to Proactively Advance Sepsis Survivorship |
| Sepsis Transition and Recovery (STAR) Program vs Usual Care: Outpatient Medication Reconciliation | 1,590 of 2,122 866 of 1,426 | 14.2 points 11.1 to 17.3 | 3,548 | NCT04495946 Implementation and Effectiveness of Engagement and Collaborative Management to Proactively Advance Sepsis Survivorship |
| Sepsis Transition and Recovery (STAR) Program vs Usual Care: Early Outpatient Provider Follow up | 468 of 2,122 348 of 1,426 | -2.3 points -5.2 to 0.5 | 3,548 | NCT04495946 Implementation and Effectiveness of Engagement and Collaborative Management to Proactively Advance Sepsis Survivorship |
| Sepsis Transition and Recovery (STAR) Program vs Usual Care: deaths from any cause | 367 of 2,122 292 of 1,426 | -3.2 points -5.9 to -0.6 | 3,548 | NCT04495946 Implementation and Effectiveness of Engagement and Collaborative Management to Proactively Advance Sepsis Survivorship |
| Sepsis Transition and Recovery (STAR) Program vs Usual Care: Cause-specific Hospital Readmission Rate | 370 of 2,122 222 of 1,426 | 1.9 points -0.6 to 4.3 | 3,548 | NCT04495946 Implementation and Effectiveness of Engagement and Collaborative Management to Proactively Advance Sepsis Survivorship |
Code
curl "https://conductscience.org/api/comparisons/v1?page=114"
Response
The first 2 of this page's 20 results. GET /api/comparisons/v1?page=114
{
"data": {
"total": 85013,
"results": [
{
"id": "NCT01755598-sae",
"title": "M72AS01 Group vs Control Group: serious adverse events",
"summary": "51 of 1786 against 62 of 1787; risk difference -0.6 points, 95% interval -1.8 to 0.5; NCT01755598, Study to Evaluate the Efficacy of GlaxoSmithKline (GSK) Biologicals' Candidate Tuberculosis (TB) Vaccine in Adults",
"record": "/library/comparisons/NCT01755598-sae",
"nct_id": "NCT01755598",
"kind": "serious-adverse-events",
"participants": 3573,
"risk_difference": {
"value": -0.0061395884548791115,
"lower": -0.017831726796408598,
"upper": 0.005441857841151643
},
"group_1": "51 of 1,786",
"group_2": "62 of 1,787",
"difference": "-0.6 points",
"interval": "-1.8 to 0.5",
"trial_title": "Study to Evaluate the Efficacy of GlaxoSmithKline (GSK) Biologicals' Candidate Tuberculosis (TB) Vaccine in Adults"
},
{
"id": "NCT01116882-6e3b09e2",
"title": "PCI at Hospitals Without On-Site Cardiac Surgery vs PCI at Hospital With On-Site Cardiac Surgery: Any Repeat Revascularization",
"summary": "73 of 2689 against 31 of 883; risk difference -0.8 points, 95% interval -2.3 to 0.4; NCT01116882, Percutaneous Coronary Intervention (PCI) Outcomes in Community Versus Tertiary Settings",
"record": "/library/comparisons/NCT01116882-6e3b09e2",
"nct_id": "NCT01116882",
"kind": "outcome",
"participants": 3572,
"risk_difference": {
"value": -0.007959949241635844,
"lower": -0.023275143336832047,
"upper": 0.004381237276717145
},
"group_1": "73 of 2,689",
"group_2": "31 of 883",
"difference": "-0.8 points",
"interval": "-2.3 to 0.4",
"trial_title": "Percutaneous Coronary Intervention (PCI) Outcomes in Community Versus Tertiary Settings"
}
],
"no_events": 33758,
"columns": [
{
"key": "title",
"label": "Comparison"
},
{
"key": "group_1",
"label": "With the outcome",
"under": "group_2"
},
{
"key": "difference",
"label": "Risk difference, 95% interval",
"under": "interval"
},
{
"key": "participants",
"label": "Participants"
},
{
"key": "nct_id",
"label": "Trial",
"under": "trial_title"
}
],
"order": "Most participants first",
"kinds": {
"all": 85013,
"outcome": 33568,
"serious-adverse-events": 31897,
"deaths": 19548
}
},
"release": "trial-comparisons-2026-03-23-0.1.0",
"terms": [
{
"source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
"license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "Freely available. Acknowledgement requested"
},
{
"source": "ClinicalTrials.gov",
"license": "none stated",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "No license stated"
}
],
"next": "/api/comparisons/v1?page=115",
"request_id": "iEJFyzipSmodBtTE"
}Ask about these results. The first 10 go in the prompt.
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
ClinicalTrials.gov
Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.
Patent publications
Paste a sequence and see the patents that disclose it.
Opens sequences.conductscience.org
For software
Every answer on this page is also JSON, under /api/comparisons/v1. No key.
GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome
Ask an assistant